Affordable Access

Access to the full text

Emerging technologies in autoantibody testing for rheumatic diseases

Authors
  • Olsen, Nancy J.1
  • Choi, May Y.2
  • Fritzler, Marvin J.2
  • 1 Penn State M.S. Hershey Medical Center, 500 University Drive, Hershey, PA, 17033, USA , Hershey (United States)
  • 2 University of Calgary, Cumming School of Medicine, Calgary, AB, T2N4N1, Canada , Calgary (Canada)
Type
Published Article
Journal
Arthritis Research & Therapy
Publisher
Springer Science and Business Media LLC
Publication Date
Jul 24, 2017
Volume
19
Issue
1
Identifiers
DOI: 10.1186/s13075-017-1380-3
Source
Springer Nature
Keywords
License
Green

Abstract

Testing for the presence of antinuclear antibodies (ANAs) is a key step in the diagnosis of systemic lupus erythematosus (SLE) and other systemic autoimmune rheumatic diseases (SARD). The standard slide-based indirect immunofluorescence (IIF) test is widely used, but is limited by a relative lack of specificity for SLE and not all SARD-ANAs are detected. Alternative immunoassays that might offer enhanced diagnostic and prognostic information have evolved, and some of these have entered clinical practice. This review summarizes the current state of ANA testing and multiplex techniques for detecting other autoantibodies, the possibility of point-of-care testing, and approaches for applications in early disease stages.

Report this publication

Statistics

Seen <100 times